skip to the content

Abbreviations list

A
AC

doxorubicin and cyclophosphamide

AE

adverse event

B
BC

breast cancer

bFGF

basic fibroblast growth factor

C
CALGB

Cancer and Leukemia Group B

CHF

congestive heart failure

CI

confidence interval

CNS

central nervous system

CRC

colorectal cancer

D
DFS

disease-free survival

DOC
 

docetaxel

DOR

duration of response

DSMB

Data Safety Monitoring Board

E
EBC

early breast cancer

EC

epirubicin and cyclophosphamide

ECOG

Eastern Cooperative Oncology Group

EGF

epidermal growth factor

EGFR

epidermal growth factor receptor

EMEA

European Medicines Agency

ER

oestrogen receptor

ESMO

European Society for Medical Oncology

F
FAC

fluorouracil, doxorubicin and cyclophosphamide

FEC

fluorouracil, epirubicin and cyclophosphamide

Flt

fms-related tyrosine kinase

FOLFIRI

folinic acid, 5-fluorouracil, irinotecan

FOLFOX

leucovorin, 5-fluorouracil, oxaliplatin

G
GBM

glioblastoma

GI

gastrointestinal

H
HER2

human epidermal growth factor-2

HIF

hypoxia-induced factor

HR

hazard ratio

I
IFL

irinotecan, fluorouracil, leucovorin

IFN

interferon-α2a

IFP

interstitial fluid pressure

IRC

independent review committee

IRF

independent review facility

ITT

intent-to-treat

J
K
KIT

stem-cell factor receptor

L
LR

locally recurrent

LV

leucovorin

LVEF

left ventricular ejection fraction

M
MAb

monoclonal antibody

mBC

metastatic breast cancer

mCRC

metastatic colorectal cancer

MIU

million units

MMP

matrix metallopeptidase

MoA

mode of action

mRCC

metastatic renal cell carcinoma

MSKCC

Memorial Sloan-Kettering Cancer Center

N
NCCN

National Comprehensive Cancer Network

NE

not evaluable

NP or NRP

neuropilin

NSCLC

non-small cell lung cancer

O
OCS

observational cohort study

ORR

objective/overall response rate

OS

overall survival

P
PAC

paclitaxel

PD

disease progression

PD-ECGF

platelet-derived endothelial cell growth factor

PDGF

platelet-derived growth factor

PFS

progression-free survival

PlGF

placental growth factor

PP

per protocol

PR

progesterone receptor

Q
q3w

every 3 weeks

QoL

quality of life

R
RCC

renal cell carcinoma

S
SLD

sum of the longest diameter of target lesions

T
TGF

transforming growth factor

TK

tyrosine kinase

TKI

tyrosine kinase inhibitor

TOI-B

trial outcome index specific for breast cancer

TOT-B

trial outcome total for breast cancer

tPA

tissue-type plasminogen activator

TTF

time to treatment failure

TTP

time to progression

U
ULN

upper limit of normal

uPA

urokinase plasminogen activator

V
VEGF

vascular endothelial growth factor

VEGFR

VEGF receptor

VHL

von Hippel–Lindau

W
Y
Z